Strikingly, ALK1+ TAMs emerged prominently upon treatment resistance, where they represented approximately 18% of the tumor monocyte/macrophage cluster in the nonresponder group (Supplemental Figure 3E). This evidence concerns the gene ACVRL1 and neoplasm.